Bayer’s Stivarga OK’d for Colon Cancer
(MedPage Today) -- Regorafenib (Stivarga), an inhibitor of multiple kinase enzymes, has been approved for use in treatment-refractory, metastatic colorectal cancer, the FDA announced Wednesday.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.